Emerging retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the healthcare community. Early clinical research have revealed significant losses in body weight and advancements in physiological markers for patients with obesity . Experts believe this novel approach could repr